Researcher Bio Dr. Friedlich's main interest is in translational research for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and for neuropsychiatric conditions, such as bipolar disorder and schizophrenia. His work spans the length of the pipeline, from target identification to clinical trials.
Dr. Friedlich helped pioneer translational suppression as a strategy for treating neurodegenerative disease. In 2007, he co-discovered a post-transcriptional regulatory element in the Parkinson's disease alpha-synuclein transcript, leading to the discovery that alpha-synuclein and the Alzheimer amyloid precursor protein are controlled through a common intracellular pathway. A number of translational suppressors are now in pre-clinical development.
Dr Friedlich is also a board-certified Psychiatirst interested in mechanism-based development of neutraceuticals for the treatment of neuropsychiatric disorders. He is co-investigator on a number of clinical trials in the Bipolar Clinic & Research Program at Mass General Hospital, and he maintains a clinical practice.